The evidence from the literature does not support the notion that
psychotropic drugs with central anticholinergic properties
(antiparkinsonian drugs, neuroleptics, antidepressants) constitute a risk
factor in tardive dyskinesia. Antiparkinsonian drugs tend to produce
reversible increases in the severity of dyskinetic movements and can be
used as pharmacological probes in the assessment of neuroleptic-induced
movement disorders.Abstract Teaser